A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects

BACKGROUND AND OBJECTIVE: BC 007 is a substance with a novel and innovative mode of action for the first-time causal treatment of chronic heart failure, associated with the occurrence of autoantibodies against the β1-adrenoceptor, and other diseases of mostly the heart and vascular system, being acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Niels-Peter, Haberland, Annekathrin, Wenzel, Katrin, Göttel, Peter, Wallukat, Gerd, Davideit, Hanna, Schulze-Rothe, Sarah, Hönicke, Anne-Sophie, Schimke, Ingolf, Bartel, Sabine, Grossmann, Matthias, Sinn, Angela, Iavarone, Laura, Boergermann, Jan H., Prilliman, Kiley, Golor, Georg, Müller, Johannes, Becker, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181550/
https://www.ncbi.nlm.nih.gov/pubmed/32222912
http://dx.doi.org/10.1007/s40261-020-00903-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181550/
https://www.ncbi.nlm.nih.gov/pubmed/32222912
http://dx.doi.org/10.1007/s40261-020-00903-9

Ejemplares similares